Your immune system doesn't age at the same rate as the rest of you — and that gap might matter more than your birthday. In this episode, Dr. Ethan Hausman-Marquis breaks down the three biological processes driving immune decline (a shrinking supply of new T cells, a growing population of "exhausted" T cells worn down by years of repeated activation, and the chronic low-grade inflammation that results) and explains why two people of the same chronological age can have wildly different immune resilience.

The episode centers on a real, recently announced UCL trial from biotech spinout SenTcell, which is preparing a first-in-human Phase 1 study aiming to metabolically reprogramme exhausted T cells back toward youthful function. Dr. Ethan walks through exactly what the trial can and can't tell us at this stage, draws a credible parallel to already-approved cancer immunotherapies that work on similar biology, and is upfront about the realistic decade-long runway between early trial and approved treatment.

Rather than stop at the hype, the episode spends real time on the open questions: could reactivating exhausted T cells tip some people toward autoimmunity, the way it sometimes does with checkpoint inhibitors? What's actually within listeners' control today — sleep, visceral fat, chronic stress, viral exposure — while the science matures? And what does "success" even mean here: not living forever, but preserving the ability to fight disease for longer.